Anti-drug antibodies in psoriasis: A critical evaluation of clinical significance and impact on treatment response

Leeyen Hsu, April W. Armstrong

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

TNF inhibitors and anti-p40IL12/23 monoclonal antibodies are efficacious treatments for moderate-to-severe psoriasis. However, the formation of anti-drug antibodies (ADA) with biologics may prevent patients from achieving a full clinical response. ADA have been reported in patients treated with etanercept, infliximab, adalimumab or ustekinumab at rates of 0-18.3%, 5.4-43.6%, 8.8-44.8% and 3.8-5.4%, respectively. Antibodies against etanercept have no apparent effects on clinical response, whereas antibodies against infliximab or adalimumab have been associated with diminished clinical response. The significance of ADA against ustekinumab is yet to be determined. Data regarding management strategies to counteract ADA formation and their effects are limited in psoriasis patients. However, some evidence suggests that concomitant immunomodulators such as methotrexate may suppress ADA development in psoriasis. ADA specific to one biologic do not appear to carry cross-linking potential with other biologic agents. ADA formation needs to be considered as a possible factor contributing to diminished response from biologic agents.

Original languageEnglish (US)
Pages (from-to)949-958
Number of pages10
JournalExpert Review of Clinical Immunology
Volume9
Issue number10
DOIs
StatePublished - 2013

Fingerprint

Psoriasis
Anti-Idiotypic Antibodies
Pharmaceutical Preparations
Antibody Formation
Biological Factors
Therapeutics
Immunologic Factors
Biological Products
Methotrexate
Monoclonal Antibodies
Antibodies

Keywords

  • adalimumab
  • anti-drug antibodies
  • etanercept
  • infliximab
  • methotrexate
  • psoriasis
  • ustekinumab

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Anti-drug antibodies in psoriasis : A critical evaluation of clinical significance and impact on treatment response. / Hsu, Leeyen; Armstrong, April W.

In: Expert Review of Clinical Immunology, Vol. 9, No. 10, 2013, p. 949-958.

Research output: Contribution to journalArticle

@article{68bc61c526d64be7b2ee2738867c3f9d,
title = "Anti-drug antibodies in psoriasis: A critical evaluation of clinical significance and impact on treatment response",
abstract = "TNF inhibitors and anti-p40IL12/23 monoclonal antibodies are efficacious treatments for moderate-to-severe psoriasis. However, the formation of anti-drug antibodies (ADA) with biologics may prevent patients from achieving a full clinical response. ADA have been reported in patients treated with etanercept, infliximab, adalimumab or ustekinumab at rates of 0-18.3{\%}, 5.4-43.6{\%}, 8.8-44.8{\%} and 3.8-5.4{\%}, respectively. Antibodies against etanercept have no apparent effects on clinical response, whereas antibodies against infliximab or adalimumab have been associated with diminished clinical response. The significance of ADA against ustekinumab is yet to be determined. Data regarding management strategies to counteract ADA formation and their effects are limited in psoriasis patients. However, some evidence suggests that concomitant immunomodulators such as methotrexate may suppress ADA development in psoriasis. ADA specific to one biologic do not appear to carry cross-linking potential with other biologic agents. ADA formation needs to be considered as a possible factor contributing to diminished response from biologic agents.",
keywords = "adalimumab, anti-drug antibodies, etanercept, infliximab, methotrexate, psoriasis, ustekinumab",
author = "Leeyen Hsu and Armstrong, {April W.}",
year = "2013",
doi = "10.1586/1744666X.2013.836060",
language = "English (US)",
volume = "9",
pages = "949--958",
journal = "Expert Review of Clinical Immunology",
issn = "1744-666X",
publisher = "Expert Reviews Ltd.",
number = "10",

}

TY - JOUR

T1 - Anti-drug antibodies in psoriasis

T2 - A critical evaluation of clinical significance and impact on treatment response

AU - Hsu, Leeyen

AU - Armstrong, April W.

PY - 2013

Y1 - 2013

N2 - TNF inhibitors and anti-p40IL12/23 monoclonal antibodies are efficacious treatments for moderate-to-severe psoriasis. However, the formation of anti-drug antibodies (ADA) with biologics may prevent patients from achieving a full clinical response. ADA have been reported in patients treated with etanercept, infliximab, adalimumab or ustekinumab at rates of 0-18.3%, 5.4-43.6%, 8.8-44.8% and 3.8-5.4%, respectively. Antibodies against etanercept have no apparent effects on clinical response, whereas antibodies against infliximab or adalimumab have been associated with diminished clinical response. The significance of ADA against ustekinumab is yet to be determined. Data regarding management strategies to counteract ADA formation and their effects are limited in psoriasis patients. However, some evidence suggests that concomitant immunomodulators such as methotrexate may suppress ADA development in psoriasis. ADA specific to one biologic do not appear to carry cross-linking potential with other biologic agents. ADA formation needs to be considered as a possible factor contributing to diminished response from biologic agents.

AB - TNF inhibitors and anti-p40IL12/23 monoclonal antibodies are efficacious treatments for moderate-to-severe psoriasis. However, the formation of anti-drug antibodies (ADA) with biologics may prevent patients from achieving a full clinical response. ADA have been reported in patients treated with etanercept, infliximab, adalimumab or ustekinumab at rates of 0-18.3%, 5.4-43.6%, 8.8-44.8% and 3.8-5.4%, respectively. Antibodies against etanercept have no apparent effects on clinical response, whereas antibodies against infliximab or adalimumab have been associated with diminished clinical response. The significance of ADA against ustekinumab is yet to be determined. Data regarding management strategies to counteract ADA formation and their effects are limited in psoriasis patients. However, some evidence suggests that concomitant immunomodulators such as methotrexate may suppress ADA development in psoriasis. ADA specific to one biologic do not appear to carry cross-linking potential with other biologic agents. ADA formation needs to be considered as a possible factor contributing to diminished response from biologic agents.

KW - adalimumab

KW - anti-drug antibodies

KW - etanercept

KW - infliximab

KW - methotrexate

KW - psoriasis

KW - ustekinumab

UR - http://www.scopus.com/inward/record.url?scp=84886937924&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84886937924&partnerID=8YFLogxK

U2 - 10.1586/1744666X.2013.836060

DO - 10.1586/1744666X.2013.836060

M3 - Article

C2 - 24128157

AN - SCOPUS:84886937924

VL - 9

SP - 949

EP - 958

JO - Expert Review of Clinical Immunology

JF - Expert Review of Clinical Immunology

SN - 1744-666X

IS - 10

ER -